Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon <i>EGFR</i> Mutations Pretreated With Reversible EGFR Inhibitors

Abstract

Afatinib is clinically active and well tolerated in many TKI-pretreated NSCLC patients harboring uncommon EGFR mutations. Compared with results reported in TKI-naïve patients, activity was also indicated in patients with T790M and exon 20 insertion mutations.